Maternal deaths in women with lupus nephritis: a review of published evidence

• Published in: Lupus Vol. 21; no. 5; pp. 534 - 541
• Main Authors: Ritchie, J, Smyth, A, Tower, C, Helbert, M, Venning, M, Garovic, VD
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.04.2012; Sage Publications Ltd
• Subjects: Cardiomyopathy; Citation indexes; Clinical trials; Electronic literature; Embolism; Female; Fetuses; Histology; Humans; Hypertension; Immunosuppressive agents; Infection; Internet; Kidney diseases; Literature reviews; Lung; Lupus; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - epidemiology; Lupus nephritis; Lupus Nephritis - complications; Lupus Nephritis - epidemiology; Maternal Mortality; Nephrology; Online data bases; Patients; Postpartum period; Pregnancy; Pregnancy Complications - mortality; Pregnancy Outcome; Pregnancy, High-Risk; Risk groups; Sepsis; Steroid hormones; Systemic lupus erythematosus; Womens health; United Kingdom > UK; maternal death; disease activity; lupus nephritis; infection; Systemic lupus erythematosus; pregnancy
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/0961203311434939

Background and objectives: Pregnancies in women with systemic lupus erythematosus (SLE) and lupus nephritis are considered high-risk due to high rates of maternal and fetal complications. However, there has not been a formal analysis addressing the issue of maternal deaths in these women. The aim of this study was to perform a literature review of the maternal deaths in women with SLE and lupus nephritis to: (1) identify the main causes of death and (2) discuss possible reasons for these causes, and strategies that may improve patient care and outcomes. Design, setting, participants, and measurement: We performed an extensive electronic literature search from 1962 to 2009 using online databases (PubMed, Embase, Lilacs, Cochrane Controlled Trials Register, Medline, and Science Citation Index). Studies were included if they reported pregnancies in patients with SLE and lupus nephritis with at least one reported maternal death. Results: We identified 13 studies that reported a total of 17 deaths in the 6 week post-partum period that were attributable to SLE and lupus nephritis. In all cases, death occurred in the setting of active disease, and was attributed either to infection in 41.2% (n = 7), or disease activity in 29.4% (n = 5). The remaining deaths were due to pulmonary embolus in 11.8% (n = 2), pregnancy-associated cardiomyopathy in 5.9% (n = 1), adrenal failure due to abrupt steroid withdrawal in 5.9% (n = 1), and undefined in 5.9% (n = 1). Conclusions: All maternal deaths in patients with SLE and lupus nephritis occurred in those with active disease, with disease activity/complications and infections (mainly opportunistic) being the two major causes. The presented evidence further supports timing of pregnancy relative to SLE activity, and the judicious use of immunosuppressive agents in pregnant patients.